Literature DB >> 16002046

Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

Sreenivas Laxmanan1,2, Stuart W Robertson2, Enfeng Wang1,3, Julie S Lau3, David M Briscoe2, Debabrata Mukhopadhyay1,3.   

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic cytokine that plays an important role in tumor growth and progression. Recent evidence suggests an alternate, albeit indirect, role of VEGF on host immune response to tumors. VEGF appears to diminish host immunity by altering the function of major antigen-presenting cells such as dendritic cells (DCs) [D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, D.P. Carbone, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin. Cancer Res. 5 (1999) 2963-2970, D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, D.P. Carbone, Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo, Blood 92 (1998) 4150-4166, T. Oyama, S. Ran, T. Ishida, S. Nadaf, L. Kerr, D.P. Carbone, D.I. Gabrilovich, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells, J. Immunol. 160 (1998) 1224-1232.]. DCs are prime initiators of host immunity as they are known to activate both primary as well as secondary immune responses [J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, K. Palucka, Immunobiology of dendritic cells, Ann. Rev. Immunol. 18 (2000) 767-811.]. However, the exact nature of how VEGF suppresses DC function is not fully clear. In this report, we show that DCs cultured in the presence of VEGF are less potent in stimulating antigen-specific T-cells. Furthermore, by using DCs derived from Id1(-/-) mice that are defective in Flt-1 signaling, we demonstrated that the inhibitory function of VEGF on DC function is most likely mediated by Flt-1. Thus, the role of VEGF in downregulating host immunity may highlight a unique role of VEGF in the pathogenesis of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002046      PMCID: PMC4495768          DOI: 10.1016/j.bbrc.2005.06.065

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

Review 1.  Dendritic cells in cancer immunotherapy.

Authors:  L Fong; E G Engleman
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.

Authors:  P Chaux; N Favre; M Martin; F Martin
Journal:  Int J Cancer       Date:  1997-08-07       Impact factor: 7.396

Review 3.  Angiogenesis and metastasis.

Authors:  L M Ellis; I J Fidler
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

Review 4.  The biology of vascular endothelial growth factor.

Authors:  N Ferrara; T Davis-Smyth
Journal:  Endocr Rev       Date:  1997-02       Impact factor: 19.871

5.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells.

Authors:  T Oyama; S Ran; T Ishida; S Nadaf; L Kerr; D P Carbone; D I Gabrilovich
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

6.  Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.

Authors:  D Lyden; K Hattori; S Dias; C Costa; P Blaikie; L Butros; A Chadburn; B Heissig; W Marks; L Witte; Y Wu; D Hicklin; Z Zhu; N R Hackett; R G Crystal; M A Moore; K A Hajjar; K Manova; R Benezra; S Rafii
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

7.  Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.

Authors:  D I Gabrilovich; T Ishida; S Nadaf; J E Ohm; D P Carbone
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

8.  Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.

Authors:  D I Gabrilovich; I F Ciernik; D P Carbone
Journal:  Cell Immunol       Date:  1996-05-25       Impact factor: 4.868

9.  Decreased antigen presentation by dendritic cells in patients with breast cancer.

Authors:  D I Gabrilovich; J Corak; I F Ciernik; D Kavanaugh; D P Carbone
Journal:  Clin Cancer Res       Date:  1997-03       Impact factor: 12.531

10.  Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells.

Authors:  G T Hoehn; T Stokland; S Amin; M Ramírez; A L Hawkins; C A Griffin; D Small; C I Civin
Journal:  Oncogene       Date:  1996-02-15       Impact factor: 9.867

View more
  29 in total

Review 1.  Spatiotemporal control over growth factor signaling for therapeutic neovascularization.

Authors:  Lan Cao; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2007-08-16       Impact factor: 15.470

2.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

Review 3.  Dendritic cells and tumor microenvironment: a dangerous liaison.

Authors:  Ingo Fricke; Dmitry I Gabrilovich
Journal:  Immunol Invest       Date:  2006       Impact factor: 3.657

Review 4.  Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Authors:  Sara Mariucci; Bianca Rovati; Mariangela Manzoni; Matteo Giovanni Della Porta; Giuditta Comolli; Sara Delfanti; Marco Danova
Journal:  Clin Exp Med       Date:  2010-12-16       Impact factor: 3.984

Review 5.  Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.

Authors:  Abhishek Tripathi; Charles G Drake; Lauren C Harshman
Journal:  BioDrugs       Date:  2014-12       Impact factor: 5.807

Review 6.  The immunosuppressive side of PDT.

Authors:  Pawel Mroz; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2011-03-24       Impact factor: 3.982

7.  Immune effects of bevacizumab: killing two birds with one stone.

Authors:  Yasir Y Elamin; Shereen Rafee; Sinead Toomey; Bryan T Hennessy
Journal:  Cancer Microenviron       Date:  2014-10-18

8.  The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Authors:  Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse
Journal:  Cancer Immunol Immunother       Date:  2008-01-10       Impact factor: 6.968

9.  A comparative study of angiogenic and cytokine responses after laparoscopic cholecystectomy performed with standard- and low-pressure pneumoperitoneum.

Authors:  Kamil Torres; Anna Torres; Grzegorz J Staśkiewicz; Andrzej Chrościcki; Tadeusz Loś; Ryszard Maciejewski
Journal:  Surg Endosc       Date:  2008-12-06       Impact factor: 4.584

Review 10.  Dendritic cell vaccine therapy for colorectal cancer.

Authors:  Amanda L Wooster; Lydia H Girgis; Hayley Brazeale; Trevor S Anderson; Laurence M Wood; Devin B Lowe
Journal:  Pharmacol Res       Date:  2020-12-28       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.